Jack Seaver

Director at CND Life Sciences

Capital raised by CND Life Sciences

$15.0M+$6.3M latest round

3 Form D filings · first filed Feb 2025

CURRENT ROLE: Director
SECTOR: Healthcare
COMPANY FILINGS: 3
TEAM ON FILE: 2
FOUNDED: —
30D INTEREST: 2 ↗

Career

1 company on file

CND Life SciencesHealthcaresince Feb 2025

Director

Listed on CND Life Sciences's Form D filings

Company filings

via EDGAR · Form D for CND Life Sciences3

DateCompanyFormAmountRole on filing

Jun 9, 2026CND Life SciencesForm D/A+$6.3M—

Form D/AJun 9, 2026 · CND Life Sciences+$6.3Mnot a signer

Jun 9, 2026CND Life SciencesForm D+$4.3M—

Form DJun 9, 2026 · CND Life Sciences+$4.3Mnot a signer

Feb 28, 2025CND Life SciencesForm D/A+$8.6M—

Form D/AFeb 28, 2025 · CND Life Sciences+$8.6Mnot a signer

Overview

Last filing Jun 9, 2026

Jack Seaver is on file as Director at CND Life Sciences. CND Life Sciences has 3 Form D filings on record, $15.0M raised in total.

Teammates

CND Life Sciences · 1

Richard J. MorelloPresident/CEOSigner

Products

CND Life Sciences · 1

Syn-One Test®Diagnostic Testing

The Syn-One Test® is a groundbreaking, minimally invasive diagnostic tool that detects and quantifies the presence of misfolded, phosphorylated alpha-synuclein in skin nerve fibers. This test is processed in a CLIA-certified and CAP-accredited laboratory through a straightforward procedure that requires three small skin biopsy samples.